Localized Cutaneous Leishmaniasis due to Leishmania infantum in a Patient Treated with Infliximab.
We report the first case of cutaneous leishmaniasis in a patient treated with infliximab. The species was Leishmania infantum, agent of both cutaneous leishmaniasis and visceral leishmaniasis. Cutaneous leishmaniasis occurred after the 9th infusion of infliximab in a patient who was suffering from ankylosing spondylitis.
Hakimi
S
S
Service de Médecine Interne A, Centre Hospitalier Universitaire, Montpellier, France. sophie78@netcourrier.com
Rivière
S
S
Del Giudice
P
P
Dereure
J
J
Le Quellec
A
A
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D018314:Leishmania infantum; D016773:Leishmaniasis, Cutaneous / Q000209:etiology* / Q000469:parasitology / Q000473:pathology; D008297:Male; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D000981:Antiprotozoal Agents; D018501:Antirheumatic Agents; D009942:Organometallic Compounds; D014409:Tumor Necrosis Factor-alpha; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000069285:Infliximab